LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 21.7
(0.93%)
TWD 21.7
(0.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 50.66 Million TWD | 24.88% |
| 2022 | 40.56 Million TWD | -19.47% |
| 2021 | 50.37 Million TWD | -25.17% |
| 2020 | 67.32 Million TWD | -59.98% |
| 2019 | 168.21 Million TWD | 354.53% |
| 2018 | 37 Million TWD | -48.1% |
| 2017 | 71.31 Million TWD | -67.98% |
| 2016 | 222.73 Million TWD | -60.81% |
| 2015 | 568.28 Million TWD | -16.17% |
| 2014 | 677.92 Million TWD | -11.24% |
| 2013 | 763.75 Million TWD | 4.76% |
| 2012 | 729.06 Million TWD | 67.3% |
| 2011 | 435.79 Million TWD | 229.39% |
| 2010 | 132.3 Million TWD | 18.58% |
| 2009 | 111.57 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 36.79 Million TWD | -28.58% |
| 2024 Q3 | 35.15 Million TWD | -4.45% |
| 2024 Q1 | 51.51 Million TWD | 1.69% |
| 2023 Q2 | 34.72 Million TWD | -28.63% |
| 2023 FY | 50.66 Million TWD | 24.88% |
| 2023 Q1 | 48.65 Million TWD | 19.93% |
| 2023 Q4 | 50.66 Million TWD | 44.95% |
| 2023 Q3 | 34.95 Million TWD | 0.66% |
| 2022 FY | 40.56 Million TWD | -19.47% |
| 2022 Q4 | 40.56 Million TWD | 10.38% |
| 2022 Q3 | 36.75 Million TWD | 0.39% |
| 2022 Q2 | 36.61 Million TWD | -27.71% |
| 2022 Q1 | 50.64 Million TWD | 0.53% |
| 2021 Q1 | 38.15 Million TWD | -43.32% |
| 2021 Q4 | 50.37 Million TWD | -26.33% |
| 2021 Q3 | 68.37 Million TWD | -8.59% |
| 2021 FY | 50.37 Million TWD | -25.17% |
| 2021 Q2 | 74.8 Million TWD | 96.04% |
| 2020 FY | 67.32 Million TWD | -59.98% |
| 2020 Q4 | 67.32 Million TWD | -5.47% |
| 2020 Q3 | 71.21 Million TWD | 3.32% |
| 2020 Q1 | 170.09 Million TWD | 1.12% |
| 2020 Q2 | 68.93 Million TWD | -59.47% |
| 2019 FY | 168.21 Million TWD | 354.53% |
| 2019 Q4 | 168.21 Million TWD | 121.67% |
| 2019 Q2 | 48.6 Million TWD | -0.35% |
| 2019 Q1 | 48.77 Million TWD | 31.8% |
| 2019 Q3 | 75.88 Million TWD | 56.14% |
| 2018 Q3 | 333.73 Million TWD | 252.33% |
| 2018 Q1 | 57.11 Million TWD | -19.9% |
| 2018 FY | 37 Million TWD | -48.1% |
| 2018 Q4 | 37 Million TWD | -88.91% |
| 2018 Q2 | 94.72 Million TWD | 65.83% |
| 2017 Q3 | 199.6 Million TWD | 319.86% |
| 2017 Q2 | 47.54 Million TWD | -58.27% |
| 2017 Q1 | 113.93 Million TWD | -48.85% |
| 2017 FY | 71.31 Million TWD | -67.98% |
| 2017 Q4 | 71.31 Million TWD | -64.27% |
| 2016 Q1 | 428.91 Million TWD | -24.52% |
| 2016 FY | 222.73 Million TWD | -60.81% |
| 2016 Q4 | 222.73 Million TWD | -51.09% |
| 2016 Q3 | 455.35 Million TWD | 10.14% |
| 2016 Q2 | 413.43 Million TWD | -3.61% |
| 2015 Q3 | 534.17 Million TWD | 0.08% |
| 2015 Q4 | 568.28 Million TWD | 6.39% |
| 2015 FY | 568.28 Million TWD | -16.17% |
| 2015 Q1 | 603.86 Million TWD | -10.92% |
| 2015 Q2 | 533.72 Million TWD | -11.61% |
| 2014 Q1 | 486.74 Million TWD | -36.27% |
| 2014 Q4 | 677.92 Million TWD | 1.58% |
| 2014 FY | 677.92 Million TWD | -11.24% |
| 2014 Q3 | 667.37 Million TWD | -19.03% |
| 2014 Q2 | 824.27 Million TWD | 69.34% |
| 2013 Q2 | 611.96 Million TWD | 15.28% |
| 2013 Q4 | 763.75 Million TWD | 21.23% |
| 2013 FY | 763.75 Million TWD | 4.76% |
| 2013 Q1 | 530.83 Million TWD | -27.19% |
| 2013 Q3 | 630.02 Million TWD | 2.95% |
| 2012 Q4 | 729.06 Million TWD | 59.07% |
| 2012 Q3 | 458.33 Million TWD | -2.44% |
| 2012 FY | 729.06 Million TWD | 67.3% |
| 2012 Q2 | 469.8 Million TWD | -11.85% |
| 2012 Q1 | 532.97 Million TWD | 22.3% |
| 2011 Q3 | 704.81 Million TWD | 175.78% |
| 2011 Q4 | 435.79 Million TWD | -38.17% |
| 2011 Q2 | 255.57 Million TWD | 1.36% |
| 2011 Q1 | 252.14 Million TWD | 90.58% |
| 2011 FY | 435.79 Million TWD | 229.39% |
| 2010 FY | 132.3 Million TWD | 18.58% |
| 2010 Q4 | 132.3 Million TWD | 0.0% |
| 2009 FY | 111.57 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grape King Bio Ltd | 3.88 Billion TWD | 98.695% |
| Standard Chem & Pharm CO., LTD. | 3.05 Billion TWD | 98.34% |
| Maywufa Company Ltd. | 794.91 Million TWD | 93.627% |
| ScinoPharm Taiwan, Ltd. | 1.35 Billion TWD | 96.267% |
| Lotus Pharmaceutical Co., Ltd. | 15.65 Billion TWD | 99.676% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | 98.592% |
| PhytoHealth Corporation | 79.84 Million TWD | 36.555% |
| SCI Pharmtech, Inc. | 1.59 Billion TWD | 96.815% |
| Formosa Laboratories, Inc. | 5.42 Billion TWD | 99.066% |
| PharmaEssentia Corporation | 3.32 Billion TWD | 98.475% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | 99.619% |